Control study of aripiprazole added on sretraline in treating refractory obsessive compulsive disorder

Objective:To evaluate the efficacy and safety of aripiprazole added on sretraline on patients with refractory obsessive compulsive disorder.Methods:All 60 refractory obsessive compulsive disorder patients were randomly divided into sretraline group(n=30,sretraline 100~200 mg/d),and aripiprazole added on sretraline group(n=30,sretraline 100~200 mg/d,aripiprazole 10~20 mg/d) and received medication treatment for 8 weeks.The efficacy was assessed with Yale-Brown obsessive-compulsive psychiatrists rating scale(Y-Brown) at the beginning and the 2nd,4th,6th,8th weekend of treatment.The side effects were assessed with the treatment emergent symptom scale(TESS).Results:There were no difference of scores of TESS among the two groups before and at the 2nd,4th,6th,8th weekend of treatment(P0.05).The Y-Brown score of aripiprazole added on sretraline group was lower than that of sretraline group(P0.05).Conclusion:Aripiprazole added on sretraline is effective and safe on patients with refractory obsessive compulsive disorder.